Lymphoma, Large-Cell, Immunoblastic × aldesleukin × Clear all
NCT00625729 2017-12-28

Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia

Masonic Cancer Center, University of Minnesota

Phase 1/2 Terminated
6 enrolled 10 charts
NCT00005993 2017-11-29

Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer

Masonic Cancer Center, University of Minnesota

Phase 1 Terminated
NCT00003414 2015-07-20

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 3 Completed
50 enrolled
NCT00003993 2015-04-29

Bryostatin 1 and Interleukin-2 in Treating Patients With Refractory Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
24 enrolled
NCT00003962 2014-05-02

Interleukin-2 Following Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
NCT00003408 2013-03-26

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

National Cancer Institute (NCI)

Phase 2 Completed
40 enrolled
NCT00002504 2011-05-12

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

Hoag Memorial Hospital Presbyterian

Phase 2 Completed
NCT00027937 2010-05-14

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Completed